Patents by Inventor Claire Y. H. Kinney
Claire Y. H. Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11648304Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.Type: GrantFiled: November 5, 2018Date of Patent: May 16, 2023Assignee: Takeda Vaccines, Inc.Inventors: Jill A. Livengood, Holli Giebler, Whitney Baldwin, Hansi Dean, Claire Y. H. Kinney
-
Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells
Patent number: 11344615Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.Type: GrantFiled: July 6, 2017Date of Patent: May 31, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Claire Y. H. Kinney -
Publication number: 20210290749Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.Type: ApplicationFiled: July 6, 2017Publication date: September 23, 2021Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventor: Claire Y. H. Kinney
-
Publication number: 20200360505Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.Type: ApplicationFiled: November 5, 2018Publication date: November 19, 2020Inventors: Jill A. LIVENGOOD, Holli GIEBLER, Whitney BALDWIN, Hansi DEAN, Claire Y.H. KINNEY
-
Patent number: 10632185Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from West Nile virus (WNV), and a portion of a prM signal sequence, a prM protein and an E protein from Zika virus (VIKV) are described. Also described are compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV. Diagnostic assays that utilize chimeric West Nile/Zika viruses are further described.Type: GrantFiled: July 6, 2017Date of Patent: April 28, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Claire Y. H. Kinney
-
Publication number: 20190298818Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from West Nile virus (WNV), and a portion of a prM signal sequence, a prM protein and an E protein from Zika virus (VIKV) are described. Also described are compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV. Diagnostic assays that utilize chimeric West Nile/Zika viruses are further described.Type: ApplicationFiled: July 6, 2017Publication date: October 3, 2019Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventor: Claire Y. H. Kinney
-
Patent number: 10428313Abstract: Disclosed herein are chimeric flaviviruses including non-coding regions, non-structural proteins, and at least a portion of a C protein from West Nile virus (WNV), and a prM protein and an E protein from Dengue virus (DENV). The DENV may be DEN1 serotype, DEN2 serotype, DEN3 serotype, or DEN4 serotype. Also disclosed herein are compositions and methods for eliciting an immune response in a subject, such as an immune response to one or more DENV serotypes. In particular embodiments, the compositions include one or more inactivated viruses including a WN/DENV chimeric nucleic acid (such as a tetravalent inactivated vaccine including a WN/DEN1 chimera, a WN/DEN2 chimera, a WN/DEN3 chimera, and a WN/DEN4 chimera). The compositions may be administered to a subject to elicit an immune response.Type: GrantFiled: June 19, 2015Date of Patent: October 1, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Claire Y. H. Kinney
-
Patent number: 10335478Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: September 6, 2016Date of Patent: July 2, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Publication number: 20170114330Abstract: Disclosed herein are chimeric flaviviruses including non-coding regions, non-structural proteins, and at least a portion of a C protein from West Nile virus (WNV), and a prM protein and an E protein from Dengue virus (DENV). The DENV may be DEN1 serotype, DEN2 serotype, DEN3 serotype, or DEN4 serotype. Also disclosed herein are compositions and methods for eliciting an immune response in a subject, such as an immune response to one or more DENV serotypes. In particular embodiments, the compositions include one or more inactivated viruses including a WN/DENV chimeric nucleic acid (such as a tetravalent inactivated vaccine including a WN/DEN1 chimera, a WN/DEN2 chimera, a WN/DEN3 chimera, and a WN/DEN4 chimera). The compositions may be administered to a subject to elicit an immune response.Type: ApplicationFiled: June 19, 2015Publication date: April 27, 2017Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventor: Claire Y. H. Kinney
-
Publication number: 20160367658Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: September 6, 2016Publication date: December 22, 2016Applicants: The Government of the USA, as represented by the Secretary, Department of Health and Human Services, Mahidol UniversityInventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Patent number: 9463233Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: January 28, 2014Date of Patent: October 11, 2016Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Patent number: 9169298Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.Type: GrantFiled: October 25, 2011Date of Patent: October 27, 2015Assignees: Centers for Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20150031857Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: ApplicationFiled: August 4, 2014Publication date: January 29, 2015Inventors: Richard KINNEY, Claire Y.H. Kinney, Veronique Barban, Jean Lang, Bruno Guy
-
Patent number: 8795688Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: GrantFiled: October 25, 2011Date of Patent: August 5, 2014Assignees: Sanofi Pasteur, Centers for Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20140141040Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicants: Mahidol University, The Government of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
-
Patent number: 8715689Abstract: The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.Type: GrantFiled: April 27, 2009Date of Patent: May 6, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Claire Y. H. Kinney, Eric Thomas Beck, Richard M. Kinney
-
Patent number: 8673316Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: August 18, 2011Date of Patent: March 18, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Publication number: 20120083585Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: ApplicationFiled: October 25, 2011Publication date: April 5, 2012Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20120083584Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.Type: ApplicationFiled: October 25, 2011Publication date: April 5, 2012Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20120014981Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: ApplicationFiled: August 18, 2011Publication date: January 19, 2012Inventors: Richard M. Kinney, Claire Y.H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati